Sign in Subscribe
Pharmaceutical industry

Ipilimumab Plus Nivolumab Shows Promise for Metastatic Non-Clear Cell Renal Cell Carcinoma

Strategic Insights

— 2 min read

Cleveland, Ohio, researchers have investigated the efficacy of ipilimumab plus nivolumab in patients with metastatic non-clear cell renal cell carcinoma, a type of kidney cancer. According to a study published in Clinical Genitourinary Cancer, the combination of these two immunotherapies demonstrated objective responses and notable toxicity in patients with this particular form of cancer. The study identified 18 patients from Cleveland Clinic and the University of Texas Southwestern who received ipilimumab plus nivolumab between October 2017 and May 2019. The median age of the patients was 59 years, and 77.8% were men. Objective responses were observed in 33.3% of patients, with a median time to best response of 3.0 months and a median duration of the response of 4.3 months. The median progression-free survival was 7.1 months.

Key Takeaways:

  • A study conducted at Cleveland Clinic and the University of Texas Southwestern investigated the efficacy of ipilimumab plus nivolumab in 18 patients with metastatic non-clear cell renal cell carcinoma, a form of kidney cancer.
  • The median age of the patients was 59 years, and 77.8% were men.
  • The combination of ipilimumab plus nivolumab demonstrated objective responses in 33.3% of patients, with a median time to best response of 3.0 months and a median duration of the response of 4.3 months.
  • The median progression-free survival was 7.1 months.
  • Notable toxicity was observed in 61.1% of patients, with colitis, hepatotoxicity, rash, and fatigue being the most common side effects.
  • The study found that new combination therapy, ipilimumab plus nivolumab, potentially holds promise for treating metastatic non-clear cell renal cell carcinoma.
  • A total of 18 patients with metastatic non-clear cell renal cell carcinoma were identified, and all patients received the combination of ipilimumab plus nivolumab.
  • The study's findings suggest that the combination of ipilimumab plus nivolumab is a viable treatment option for patients with metastatic non-clear cell renal cell carcinoma.

Statistics:

  • 18 patients with metastatic non-clear cell renal cell carcinoma were identified.
  • 77.8% of the patients were men.
  • The median age was 59 years (range, 32-81 years).
  • 33.3% of patients demonstrated objective responses to the treatment.
  • The median time to best response was 3.0 months.
  • The median duration of the response was 4.3 months.
  • The median progression-free survival was 7.1 months.
  • 61.1% of patients experienced notable toxicity, with colitis, hepatotoxicity, rash, and fatigue being the most common side effects.

Sources:

  • Clinical Activity of Ipilimumab Plus Nivolumab In Patients With Metastatic Non- Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020;18(6):429-435.
  • Clinical Genitourinary Cancer can be contacted at: Elsevier, 3500 Maple Avenue, Ste 750, Dallas, TX 75219-3931, USA. (Elsevier - www.elsevier.com; Clinical Genitourinary Cancer - www.journals.elsevier.com/clinical-genitourinary-cancer/)

Read more